FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019693766> ?p ?o ?g. }

• W2019693766 endingPage "1135" @default.
• W2019693766 startingPage "1126" @default.
• W2019693766 abstract "Intergroupe Francophone de Cancérologie Thoracique-0401 phase II trial aimed to evaluate the efficacy and safety of gefitinib as a first-line treatment for patients with adenocarcinoma with bronchioloalveolar carcinoma subtype (ADC-BAC).Chemotherapy-naive patients (n = 88) with advanced ADC-BAC were treated with 250 mg/d of gefitinib. The primary objective was assessment of disease control rate (DCR [objective response + stable disease]) at 3 months using World Health Organization criteria. A disease control rate of 25% or greater would be of interest in this patient population. Progression-free survival (PFS), overall survival (OS), and toxicity were the secondary criteria. Clinical and disease characteristics that conferred a favorable prognosis under gefitinib were also analyzed.Disease control was achieved in 25 patients (29.4%); 11 patients (12.9%) had partial response and 14 (16.4%) had stable disease. Median PFS was 2.9 months (95% confidence interval [CI], 2.3-3.2) and median OS was 13.2 months (95% CI, 10.2-17.3). Never smokers, patients with low respiratory symptoms score, occurrence of cutaneous rash, and nonmucinous ADC-BAC subtype were associated with increased probability of disease control. Nonmucinous ADC-BAC was associated with increased PFS and OS at 3 years. Patients with nonmucinous BAC had longer OS and PFS compared with patients with other ADC-BAC variants; median PFS for nonmucinous BAC was 11.3 months (95% CI, 3.2-14.7), whereas it was 2.6 months (95% CI, 2.1-3) for mucinous BAC. As expected, toxicity was low, with dermatological problems, diarrhea, and nausea being the most common adverse events.Results from the Intergroupe Francophone de Cancérologie Thoracique-0401 trial demonstrate that gefitinib combines efficacy with low toxicity and is, therefore, suitable as a first-line treatment of advanced ADC-BAC, particularly in patients with nonmucinous BAC subtype." @default.
• W2019693766 created "2016-06-24" @default.
• W2019693766 creator A5001498932 @default.
• W2019693766 creator A5005673716 @default.
• W2019693766 creator A5008724268 @default.
• W2019693766 creator A5015179583 @default.
• W2019693766 creator A5021624793 @default.
• W2019693766 creator A5026113531 @default.
• W2019693766 creator A5027068255 @default.
• W2019693766 creator A5044328939 @default.
• W2019693766 creator A5074670245 @default.
• W2019693766 creator A5083786421 @default.
• W2019693766 date "2009-09-01" @default.
• W2019693766 modified "2023-10-09" @default.
• W2019693766 title "IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype" @default.
• W2019693766 cites W1967394241 @default.
• W2019693766 cites W1988442083 @default.
• W2019693766 cites W1992184657 @default.
• W2019693766 cites W1996994323 @default.
• W2019693766 cites W2010329596 @default.
• W2019693766 cites W2011864516 @default.
• W2019693766 cites W2013350063 @default.
• W2019693766 cites W2021658870 @default.
• W2019693766 cites W2023437574 @default.
• W2019693766 cites W2043103956 @default.
• W2019693766 cites W2043696829 @default.
• W2019693766 cites W2052009184 @default.
• W2019693766 cites W2058267266 @default.
• W2019693766 cites W2059780149 @default.
• W2019693766 cites W2066810596 @default.
• W2019693766 cites W2089750734 @default.
• W2019693766 cites W2092444137 @default.
• W2019693766 cites W2095635764 @default.
• W2019693766 cites W2095673635 @default.
• W2019693766 cites W2096340454 @default.
• W2019693766 cites W2096418206 @default.
• W2019693766 cites W2101329867 @default.
• W2019693766 cites W2102119601 @default.
• W2019693766 cites W2106726143 @default.
• W2019693766 cites W2111710483 @default.
• W2019693766 cites W2120718661 @default.
• W2019693766 cites W2125195105 @default.
• W2019693766 cites W2127160299 @default.
• W2019693766 cites W2130254323 @default.
• W2019693766 cites W2133282712 @default.
• W2019693766 cites W2138297714 @default.
• W2019693766 cites W2143410956 @default.
• W2019693766 cites W2146404049 @default.
• W2019693766 cites W2153477391 @default.
• W2019693766 cites W2153613476 @default.
• W2019693766 cites W2160866033 @default.
• W2019693766 cites W2161821474 @default.
• W2019693766 cites W2162705771 @default.
• W2019693766 cites W2164194457 @default.
• W2019693766 cites W2167805334 @default.
• W2019693766 cites W2330814896 @default.
• W2019693766 cites W4293241248 @default.
• W2019693766 doi "https://doi.org/10.1097/jto.0b013e3181abeb5d" @default.
• W2019693766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19574932" @default.
• W2019693766 hasPublicationYear "2009" @default.
• W2019693766 type Work @default.
• W2019693766 sameAs 2019693766 @default.
• W2019693766 citedByCount "53" @default.
• W2019693766 countsByYear W20196937662012 @default.
• W2019693766 countsByYear W20196937662013 @default.
• W2019693766 countsByYear W20196937662014 @default.
• W2019693766 countsByYear W20196937662015 @default.
• W2019693766 countsByYear W20196937662016 @default.
• W2019693766 countsByYear W20196937662017 @default.
• W2019693766 countsByYear W20196937662018 @default.
• W2019693766 countsByYear W20196937662019 @default.
• W2019693766 countsByYear W20196937662020 @default.
• W2019693766 countsByYear W20196937662021 @default.
• W2019693766 crossrefType "journal-article" @default.
• W2019693766 hasAuthorship W2019693766A5001498932 @default.
• W2019693766 hasAuthorship W2019693766A5005673716 @default.
• W2019693766 hasAuthorship W2019693766A5008724268 @default.
• W2019693766 hasAuthorship W2019693766A5015179583 @default.
• W2019693766 hasAuthorship W2019693766A5021624793 @default.
• W2019693766 hasAuthorship W2019693766A5026113531 @default.
• W2019693766 hasAuthorship W2019693766A5027068255 @default.
• W2019693766 hasAuthorship W2019693766A5044328939 @default.
• W2019693766 hasAuthorship W2019693766A5074670245 @default.
• W2019693766 hasAuthorship W2019693766A5083786421 @default.
• W2019693766 hasBestOaLocation W20196937661 @default.
• W2019693766 hasConcept C121608353 @default.
• W2019693766 hasConcept C126322002 @default.
• W2019693766 hasConcept C141071460 @default.
• W2019693766 hasConcept C143998085 @default.
• W2019693766 hasConcept C2776694085 @default.
• W2019693766 hasConcept C2777546739 @default.
• W2019693766 hasConcept C2778570526 @default.
• W2019693766 hasConcept C2779438470 @default.
• W2019693766 hasConcept C2780580887 @default.
• W2019693766 hasConcept C2781182431 @default.
• W2019693766 hasConcept C2908647359 @default.
• W2019693766 hasConcept C31760486 @default.
• W2019693766 hasConcept C71924100 @default.

• next